ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

PCCA Introduces Innovative New Compounding Base – SuspendIt® Anhydrous

Houston, Jan. 11, 2023 (GLOBE NEWSWIRE) -- PCCA’s innovative new oral suspending base, SuspendIt Anhydrous, is ideal for active pharmaceutical ingredients (APIs) that are unstable in water or have incompatibilities with existing aqueous vehicles.

“An anhydrous base offers many benefits to compounding pharmacies,” PCCA Chief Scientific Officer Gus Bassani said. “There’s no water to support the growth of micro-organisms or cause hydrolytic degradation of an API and it opens the potential for formulations to be assigned longer beyond-use dates (BUDs). But what makes our new base really unique is its self-emulsifying properties. This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility as well.”

The majority of anhydrous bases currently on the market are oil-based; however, many patients — especially children — do not like the taste of oil-based vehicles, nor do they like the oily residue left in their mouths and throats. These and other issues lead to problems with medication compliance.

“We developed a unique anhydrous base that, in addition to the self-emulsifying properties, has an improved viscosity, which reduces when shaken and thickens when standing. This thixotropic effect allows for rapid redispersion of APIs with agitation and minimizes sedimentation,” PCCA Director of Research and Development Daniel Banov said. “We added a natural sweetener, as well as the ability to mix the compounded medicine with juice or water at the moment of administration, for a better taste if desired. The technology is so unique that we have a patent pending.”

Developing the unique anhydrous base was a collaborative effort. “Our Research and Development team, as well as our Formulations, Quality Control and Operations teams, collaborated, performing multiple uniformity and stability studies on SuspendIt Anhydrous. We also tested the base’s performance in nasogastric feeding tubes and were very pleased with the results,” Bassani said.

Additionally, PCCA has created formulas for the most commonly prescribed APIs and plans to continue formula development and API testing. Formulas and studies are available to PCCA members.

Additional product information is available in the PCCA Product Catalog at pccarx.com.

# # #

ABOUT PCCA

PCCA supports the creation of personalized medicine and innovative products that make a difference in patients’ lives. As a complete resource for independent compounding pharmacies and health systems, PCCA provides high-quality products, education and support to more than 3,000 pharmacy members throughout the United States, Canada, Australia and other countries around the world. Incorporated in 1981 by a network of pharmacists, PCCA has supported pharmacy compounding for more than 40 years. Learn more at pccarx.com.

Attachment


Kim Speairs, APR, MBA
PCCA
817.729.5064
kspeairs@pccarx.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  223.00
+0.46 (0.21%)
AAPL  275.12
+1.01 (0.37%)
AMD  209.31
+1.73 (0.83%)
BAC  54.91
-0.42 (-0.76%)
GOOG  307.41
-1.91 (-0.62%)
META  661.01
+13.50 (2.08%)
MSFT  476.30
+1.48 (0.31%)
NVDA  177.73
+1.44 (0.82%)
ORCL  188.93
+4.01 (2.17%)
TSLA  489.42
+14.11 (2.97%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.